4 results
The primary objective will be to assess whether cerebrovascular reactivity is impaired in patients with steno-occlusive disease of the vertebrobasilar artery .
1. What is the effect of a clinical oral dose of acetazolamide on the isocapnic hypoxic response (IHR), i.e. an exposure to hypoxia (end-tidal PO2 ~ 5.8 kPa) during 30 min? Does the agent increase the IHR as would be expected from the state of…
The primary objective is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best…
In a phase II study we will evaluate safety and proof-of-concept of acetazolamide in patients with aneurysmal SAH. The primary aim of this study is to evaluate whether acetazolamide improves cerebral perfusion as measured with magnetic resonance…